20 Patents in a Year? Why Patent Quantity Is a Dangerous KPI
Patent volume can signal execution–but it doesn’t equal IP strength. Learn what actually drives patent value: claim relevance, enforceability, market fit, and portfolio coherence.
A recent LinkedIn post celebrated a patent attorney’s achievement: 20 granted patents for a young startup in one year.
That’s a real accomplishment — it reflects strong execution, coordination, and follow-through.
At the same time, patent volume on its own can be an incomplete indicator of IP strength.
Because patents aren’t just outputs — they’re long-term strategic and financial commitments. And as portfolios scale, the question shifts from “how many” to:
Which patents create leverage — and which ones create cost without clear strategic impact?
Patent value is not a number. It’s leverage.
A patent has value only to the extent that it creates strategic advantage. In practice, that advantage comes from one (or more) of the following:
- Revenue protection: blocking competitors from copying what actually drives sales
- Negotiation leverage: improving your position in licensing, cross-licensing, or settlement discussions
- Risk reduction: lowering exposure to third-party assertions
- Deal support: strengthening diligence narratives in funding rounds or M&A
Crucially, none of these outcomes are guaranteed by the mere existence of a patent — let alone by the number of patents in a portfolio.
What actually drives patent value?
Across valuation models (income-based, market-based, cost-based), the same factors keep resurfacing:
1. Claim relevance to real products
A patent matters only if its claims read on:
- your product,
- a competitor’s product,
- or a critical implementation path in the market.
Patents that protect unused embodiments or speculative architectures rarely convert into leverage.
2. Enforceability under pressure
Strong patents survive:
- validity challenges,
- claim construction battles,
- and prosecution-history scrutiny.
Weakly supported claims or sloppy prosecution history turn “granted patents” into paper liabilities.
3. Market timing and scope
A narrowly drafted patent in a large, fast-moving market can be more valuable than dozens of broad but irrelevant filings in stagnant niches.
4. Portfolio-level coherence
Portfolios generate value when assets work together — covering variations, blocking design-arounds, and supporting credible enforcement narratives.
Simple patent counts fail to capture any of this.
Is prosecution speed a proxy for patent quality?
Short answer: no.
Fast prosecution can be strategically useful — for signaling, fundraising milestones, or early negotiations. But it is not a reliable predictor of value.
Empirical studies of litigated patents show that:
- longer or more complex prosecution does not necessarily produce stronger patents,
- and more office actions can correlate with a higher likelihood of invalidation.
Speed affects timing, not substance.
A fast-granted patent with weak claims is still weak.
A carefully prosecuted patent aligned with business strategy remains valuable — regardless of how long it took.
Does a larger patent portfolio mean higher company value?
This is where the “20 patents” narrative becomes actively dangerous.
Quantity increases costs — guaranteed
Every granted patent creates a future maintenance obligation:
- recurring fees,
- jurisdiction-specific renewals,
- and administrative overhead.
These costs compound over time. A large portfolio without a pruning strategy turns into a structural cash drain, often years before the company sees meaningful IP-driven returns.
Quantity does not guarantee investor appreciation
Sophisticated investors and acquirers no longer ask:
“How many patents do you have?”
They ask:
- Which patents protect revenue?
- Which ones block competitors?
- Which assets would you actually enforce?
- What’s the long-term maintenance exposure?
A bloated portfolio often raises diligence red flags, rather than confidence.
Patent quantity vs. patent quality: a false tradeoff?
The real metric that matters
The only patent quality metric that survives contact with reality is this:
Does this patent create a strategic advantage that justifies its lifetime cost?
If the answer is unclear, the patent is not an asset yet — it’s a liability in waiting.
Over time, portfolios built around “more is better” tend to collapse under:
- renewal fee pressure,
- internal prioritization conflicts,
- and weak enforcement narratives.
Portfolios built around strategic relevance tend to get smaller — and stronger.
What to do next week: a practical reset
If you’re building or managing a patent portfolio today, here are five actions that matter more than filing another application:
1. Map patents to revenue
For each granted patent or pending family, ask:
- Which product or feature does this protect?
- What percentage of company value depends on it?
No answer = low priority.
2. Identify competitor-blocking claims
Highlight patents whose claims plausibly read on:
- current competitors,
- or the most likely future entrants.
These are your leverage assets.
3. Audit maintenance intent
For each asset, document:
- Would we pay the next renewal fee?
- Why?
If the justification feels weak, act early — not after costs accumulate.
4. Reframe KPIs internally
Stop reporting:
- number of filings,
- number of grants.
Start reporting:
- patents aligned with revenue,
- patents aligned with competitive threats,
- patents justified for long-term maintenance.
5. Design future filings backward from strategy
File fewer patents — but file them:
- where enforcement would actually happen,
- with claims drafted for negotiation, not just allowance.
Final thought
Securing 20 patents in a year may look like momentum.
But strategic patent value is not about speed or volume.
It’s about building durable advantage — and avoiding a future where yesterday’s “wins” become tomorrow’s maintenance burden.
At PioneerIP, we believe patent quality should be measured by strategic impact, not portfolio size.
Everything else is just counting.
